| Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity P van Galen, V Hovestadt, MH Wadsworth II, TK Hughes, GK Griffin, ... Cell 176 (6), 1265-1281. e24, 2019 | 743 | 2019 |
| A critical role for complement in maintenance of self-tolerance AP Prodeus, S Goerg, LM Shen, OO Pozdnyakova, L Chu, EM Alicot, ... Immunity 9 (5), 721-731, 1998 | 464 | 1998 |
| Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance LM Kats, M Reschke, R Taulli, O Pozdnyakova, K Burgess, P Bhargava, ... Cell stem cell 14 (3), 329-341, 2014 | 238 | 2014 |
| B lymphocyte memory: role of stromal cell complement and FcγRIIB receptors RA Barrington, O Pozdnyakova, MR Zafari, CD Benjamin, MC Carroll The Journal of experimental medicine 196 (9), 1189-1200, 2002 | 174 | 2002 |
| Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities O Pozdnyakova, PM Miron, G Tang, O Walter, A Raza, B Woda, SA Wang Cancer 113 (12), 3331-3340, 2008 | 151 | 2008 |
| Clinical significance of CBC and WBC morphology in the diagnosis and clinical course of COVID-19 infection O Pozdnyakova, NT Connell, EM Battinelli, JM Connors, G Fell, AS Kim American journal of clinical pathology 155 (3), 364-375, 2021 | 127 | 2021 |
| Complement C4 is protective for lupus disease independent of C3 S Einav, OO Pozdnyakova, M Ma, MC Carroll The Journal of Immunology 168 (3), 1036-1041, 2002 | 112 | 2002 |
| Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and … SA Wang, O Pozdnyakova, JL Jorgensen, LJ Medeiros, D Stachurski, ... Haematologica 94 (1), 29, 2009 | 111 | 2009 |
| Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases … D Stachurski, BR Smith, O Pozdnyakova, M Andersen, Z Xiao, A Raza, ... Leukemia research 32 (2), 215-224, 2008 | 108 | 2008 |
| Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3-and complement receptor 2-deficient mice O Pozdnyakova, HK Guttormsen, FN Lalani, MC Carroll, DL Kasper The Journal of Immunology 170 (1), 84-90, 2003 | 103 | 2003 |
| Anti‐DNA autoreactivity in C4‐deficient mice E Paul, OO Pozdnyakova, E Mitchell, MC Carroll European journal of immunology 32 (9), 2672-2679, 2002 | 97 | 2002 |
| Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita D Nachmani, AH Bothmer, S Grisendi, A Mele, D Bothmer, JD Lee, ... Nature genetics 51 (10), 1518-1529, 2019 | 93 | 2019 |
| Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion P Bachireddy, U Hainz, M Rooney, O Pozdnyakova, J Aldridge, W Zhang, ... Blood, The Journal of the American Society of Hematology 123 (9), 1412-1421, 2014 | 93 | 2014 |
| Involvement of the bulge region in primary scarring alopecia O Pozdnyakova, M Mahalingam Journal of cutaneous pathology 35 (10), 922-925, 2008 | 73 | 2008 |
| DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance K Togami, T Pastika, J Stephansky, M Ghandi, AL Christie, KL Jones, ... The Journal of clinical investigation 129 (11), 5005-5019, 2019 | 65 | 2019 |
| Cyclin D1 is expressed in neoplastic cells of Langerhans cell histiocytosis but not reactive Langerhans cell proliferations V Shanmugam, JW Craig, JL Hornick, EA Morgan, GS Pinkus, ... The American Journal of Surgical Pathology 41 (10), 1390-1396, 2017 | 58 | 2017 |
| Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome G Yue, S Hao, O Fadare, S Baker, O Pozdnyakova, N Galili, BA Woda, ... Leukemia research 32 (4), 553-558, 2008 | 57 | 2008 |
| PRM-151 in myelofibrosis: efficacy and safety in an open label extension study S Verstovsek, RP Hasserjian, O Pozdnyakova, I Veletic, RA Mesa, L Foltz, ... Blood 132, 686, 2018 | 54 | 2018 |
| Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2 O Pozdnyakova, A Orazi, K Kelemen, R King, KK Reichard, FE Craig, ... American journal of clinical pathology 155 (2), 160-178, 2021 | 53 | 2021 |
| Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis C Jamieson, R Hasserjian, J Gotlib, J Cortes, R Stone, M Talpaz, J Thiele, ... Journal of translational medicine 13, 1-8, 2015 | 53 | 2015 |
